Celsis International Ltd. is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies. Headquartered in Chicago (USA), Celsis was founded in Cambridge, England (UK) by serial entrepreneur Sir Christopher Evans. Celsis was listed on the London Stock Exchange from 1993 until October 2009, when it was purchased by a private equity company. Each Celsis division delivers substantial time and cost savings to customers whilst ensuring product quality and safety for consumers: Celsis Rapid Detection division is the world leader in rapid microbial methods (RMM). Utilizing proprietary enzyme technology, we develop and supply screening systems (instruments, software, reagents and services) for the rapid detection of microbial contamination in pharmaceutical and consumer products. Our rapid testing systems provide significant economic value by reducing the time it takes companies to test and release their raw materials, in-process goods and finished products to market. Celsis Analytical Services division provides cost effective outsourced laboratory testing services to pharmaceutical, biopharmaceutical, medical device and consumer products companies. Our comprehensive offerings include a full spectrum of analytical chemistry and microbiological laboratory services plus stability testing and storage programs. Celsis can conduct up to 90% of USP compendial methods testing, and we offer the fastest routine turnaround time in the industry. Celsis In Vitro Technologies is known worldwide as a pioneer and leader in ADME-Tox products for more efficient drug discovery and development. Our proprietary expertise in hepatocytes (liver cell) and cryopreservation technology enables us to supply innovative in vitro testing products to the pharmaceutical and biotechnology industries. By screening new chemical entities for liver toxicity early in the drug discovery process, companies reduce the time and cost of further development or trial on chemical compounds that will not be properly metabolized by the human liver. |
|
